Biotechnology

MIRXES-B

MIRXES-B Establishes Independent Committee to Address Deloitte's Annual Report Audit Issues

Mirxes-B Delays Publication of 2025 Annual Report

MIRXES-B to release FY2025 earnings on March 31, 2026 (BJT), forecast revenue HKD 202.17 M, EPS HKD -1.6251

MIRXES-B wins China's first government procurement gastric cancer screening project

MIRXES-B and Apollo Sign Memorandum of Understanding for Cancer Early Detection Collaboration

MIRXES-B Completes Enrollment for Colorectal Cancer Screening Blood Test Clinical Study

MIRXES Plans to Sell New Shares to Raise HK$673 Million

Mirxes Holding Co. Ltd. Conducts a Private Placement of HK$711 Million

MIRXES-B Launches Home Helicobacter Pylori and Fecal Occult Blood Screening Kits

Mirxes Holding and N Health Launch MicroRNA Cancer Screening Solution in Thailand

MIRXES-B and XtalPi Collaborate to Build AI-Enabled Diagnostics and Treatment Integration Platform

FOSUN Securities Recommends MIRXES-B with Strong Growth Prospects

Mirxes Holding Co. Ltd. Obtains NMPA Approval for GASTROClear™ Device as a Class III Medical Device

MIRXES-B and Xeraya Form Joint Venture for Cancer Detection

MIRXES-B released FY2024 Q2 earnings on August 25 BJT with actual revenue of HKD 37.35 M and EPS of HKD -1.4455

MIRXES-B released FY2025 Q1 earnings on August 25 (BJT), actual revenue HKD 40.73 M, actual EPS HKD -0.7204

MIRXES-B released FY2025 Q2 earnings on August 25 (BJT) with actual revenue of HKD 41.1 M and EPS of HKD -0.7269

MIRXES-B released FY2024 Q1 earnings on August 25 (BJT), actual revenue HKD 37.43 M, actual EPS HKD -1.4486

MIRXES-B released FY2024 Semi-Annual earnings on August 25 (BJT), actual revenue HKD 74.79 M, actual EPS HKD -2.8942

MIRXES-B released FY2025 Semi-Annual Earnings on August 25 BJT, actual revenue HKD 81.83 M, actual EPS HKD -1.4473

CH DEMETER FIN

FAMEGLOW

LUEN THAI

NEW GONOW RV

REF HOLDINGS

PARADISE ENT

WEBX HOLDING

HAICHANG HLDG

BEST FOOD HLDG

INTELLIMARK W27

02629

513060

Mirxes Holding Company Limited (HK:2629) is facing an ongoing trading suspension due to unresolved auditor concerns regarding significant prepayments and large cash outflows. KPMG has raised questions about the selection process for service providers and the reasonableness of contract terms. The company reported material cash outflows totaling approximately US$57 million and RMB10 million for investments and advisory fees. These issues are under review by an independent investigation committee, affecting Mirxes' governance and trading resumption conditions. The company focuses on expanding its laboratory testing and manufacturing capabilities in the life sciences sector.

Tip Ranks

Bosera Hang Seng Health Care ETF(QDII)

First Trust NYSE Arca Biotech Index Fd

E Fund CSI HK Equities Medical and Health Integration ETF

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

E Fund CSI Biotechnology Theme ETF

ChinaAMC CSI Biotechnology Theme ETF

China Merchants CSI Biotechnology Theme ETF

Minsheng Royal CSI Biotechnology Theme ETF

Hwabao WP CSI Medical Service ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Mirxes Faces Ongoing Trading Suspension as Auditors Probe Prepayments and Large Cash Outflows

Mirxes Holding Company Limited has received a roadmap from the Hong Kong Stock Exchange to resume trading after a suspension due to delays in its 2025 annual results. The company must conduct an independent forensic investigation into certain transactions, demonstrate management integrity, and rectify internal control deficiencies. Full resumption of trading is contingent on meeting regulatory requirements and restoring market confidence. Mirxes is working with compliance adviser Somerley Capital Limited during this period. The company is listed on the Hong Kong Stock Exchange and focuses on compliance in financial reporting and corporate governance.

SOMERLEY CAP

Mirxes Given Regulatory Roadmap to Resume Trading After Results Delay

Hong Kong biotechnology company Mirxes has delayed the announcement of its fiscal year 2025 results due to auditors needing more time to review advance payments. The company was originally scheduled to release its results on March 31 but has announced that its stock will be suspended from trading starting April 1. The board has decided not to publish unaudited accounts to avoid confusion. The annual report and board meeting will also be postponed until the results are announced

Zaobao

Due to the auditor's review of advance payments, MiRui failed to release its performance on time | Lianhe Zaobao

Singapore biotech company Mirxes has missed its deadline to publish full-year 2025 results due to auditor concerns over prepayments to vendors. As a result, trading of its shares was suspended on April 1, 2026. The company is gathering information for the audit and has opted not to release unaudited accounts to avoid confusion. Mirxes, which specializes in cancer diagnostics, went public on the HKEX in May 2025, raising approximately HK$1.09 billion. It reported a net loss of US$92.33 million in 2024 and last traded at HK$12.58 before the announcement.

Businesstimes News

Singapore biotech Mirxes misses 2025 results deadline as auditors probe vendor payments

MIRXES-B announced that due to the company's auditor needing more time to assess certain advance payments made to service providers and suppliers, the company expects it will be unable to publish its annual results for 2025 by March 31, 2026. Trading of the company's shares on the Stock Exchange is currently expected to be suspended from 9:00 AM on April 1, 2026, until the company publishes its annual results for 2025

AASTOCKS

MIRXES delays the publication of its 2025 performance and has been suspended from trading since this morning

06636

06090

03881

00568

02068

02291

09903

02276

02160

EXTREME VISION(06636) fell 28%, with a trading turnover 236.3 Million HKD, and a year-to-date rose 80%. MIRXES-B(02629) fell 20.24%, with a trading turnover 800.0 Million HKD, and a year-to-date fell 71.8%. BUTONG GROUP(06090) fell 20.01%, with a trading turnover 63.6 Million HKD, and a year-to-date fell 59.2%.

Top Gainers&Losers

EXTREME VISION

BUTONG GROUP

CIDI

SHANDONG MOLONG

CHALIECO

SCIENTECH

ILUVATAR COREX

CONANT OPTICAL

MP CARDIOFLOW-B

Top 10 HK Stock Losers (3.31)

08368

The market overview of Hong Kong stocks in the past hour shows that market sentiment is quite tense, with a clear trend of differentiation across the board. Technology stocks and the new energy sector have suffered significant declines, especially BUTONG GROUP and MIRXES-B, both of which fell over 16%, indicating an increased risk aversion among investors in these areas. Meanwhile, some individual stocks like TIAN TU CAPITAL have risen against the trend, attracting the attention of short-term funds and creating a stark contrast. Overall, the market has experienced considerable volatility, and short-term enthusiasm seems to be switching rapidly, leading to cautious investor sentiment. In the past hour, the stock with the largest abnormal movement was BUTONG GROUP, which dropped 20.37%, becoming the market's focus. The stock attempted to rebound in the early session but was quickly suppressed by selling pressure, reflecting concerns about its future prospects. The emotional fluctuations of short-term traders were evident, resulting in a surge in trading volume for this stock. Strong stocks: 1. TIAN TU CAPITAL: up 13.18%, rising against the general market decline, attracting significant capital inflow, indicating strong buying support. 2. GW TERROIR: up 11.86%, showing stable performance recently, with the market holding an optimistic view on its future development, leading to continuous capital inflow. 3. JIAXIN INTL RES: up 11.18%, performing outstandingly in the resource sector, with active short-term funds driving its price upward. Pressured stocks: 1. MIRXES-B: down 16.39%, with increasing market concerns about its future profitability, leading to a sharp decline in its stock price

HK Stock Alerts

CREATIVE CHINA

ADD NEW ENERGY

EVEREST GOLD

TIAN TU CAPITAL

BASIC H NEWLIFE

SHANGHAI GROWTH

GW TERROIR

JIAXIN INTL RES

51WORLD

PETRO-KING

Hong Kong Stock Movement Quick Report: Market sentiment is sluggish, BUTONG GROUP plummeted by 20.37%, MIRXES-B fell by 16.39%, while TIAN TU CAPITAL rose against the trend by 13.18%

MIRXES-B fell 12.72%; Sanofi fell 6.10%, with a transaction volume of HKD 1.116 billion; Innovent Biologics fell 1.68%, with a transaction volume of HKD 716 million; CanSino Biologics fell 2.25%, with a transaction volume of HKD 643 million; BeiGene rose 0.70%, with a market value of HKD 265.4 billion

Hong Kong Stock Movement: MIRXES-B fell 12.72%, with no significant news but showing volatility. What is driving the market sentiment?

MIRXES-B(02629.HK)